Comparative Pharmacology
Head-to-head clinical analysis: CU 7 versus NIKKI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CU 7 versus NIKKI.
CU-7 vs NIKKI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
The Cu-7 intrauterine device (IUD) releases copper ions, which inhibit sperm motility and viability, and alter the endometrial environment to prevent implantation.
NIKKI is a combination oral contraceptive containing ethinyl estradiol and drospirenone. Drospirenone is a progestin with antimineralocorticoid and antiandrogenic activity. It suppresses gonadotropin release, thereby inhibiting ovulation.
50 mg orally once daily
One tablet (0.02 mg ethinyl estradiol / 3 mg drospirenone) orally once daily for 21 days, followed by 7 days of placebo.
None Documented
None Documented
Not applicable; intrauterine device with no systemic elimination half-life. Copper release is continuous with a rate of approximately 38 µg/day, declining over time.
Terminal elimination half-life: 12-15 hours; clinical context: allows once-daily dosing; steady-state reached in ~3 days
Primarily fecal (80-90%) as unabsorbed copper; negligible renal excretion (<1%).
Renal: 50% (20% unchanged, 30% as metabolites); Fecal: 40%; Biliary: 10%
Category C
Category C
Contraceptive
Contraceptive